[
  {
    "bcr_patient_uuid": "5195C9AC-B649-49F8-8750-F9A4787E8E52",
    "patient_ID": "TCGA.2Z.A9J3",
    "bcr_drug_barcode": "TCGA-2Z-A9J3-D65744",
    "bcr_drug_uuid": "686D5742-2924-4E7C-B54D-744767ECBC56",
    "form_completion_date": "2014-10-24",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 83,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 295,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "5195C9AC-B649-49F8-8750-F9A4787E8E52",
    "patient_ID": "TCGA.2Z.A9J3",
    "bcr_drug_barcode": "TCGA-2Z-A9J3-D65745",
    "bcr_drug_uuid": "62E749A7-1453-4027-A2D1-B40169B0A38C",
    "form_completion_date": "2014-10-24",
    "pharmaceutical_therapy_drug_name": "NAXAVAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 829,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1058,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5195C9AC-B649-49F8-8750-F9A4787E8E52",
    "patient_ID": "TCGA.2Z.A9J3",
    "bcr_drug_barcode": "TCGA-2Z-A9J3-D65746",
    "bcr_drug_uuid": "F3F6383C-AE79-47C8-9BAB-D5BC7479655A",
    "form_completion_date": "2014-10-24",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1058,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1765,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DEACE3D5-26FC-44D3-9F39-B5CDE2C94152",
    "patient_ID": "TCGA.4A.A93X",
    "bcr_drug_barcode": "TCGA-4A-A93X-D67791",
    "bcr_drug_uuid": "5250BD71-A670-4EAC-BE4E-AF7705C1BD14",
    "form_completion_date": "2014-11-11",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f7a2b87f-c265-4cc5-a792-428756e31d8b",
    "patient_ID": "TCGA.A4.7287",
    "bcr_drug_barcode": "TCGA-A4-7287-D57040",
    "bcr_drug_uuid": "AA8D554D-EA01-441D-9ED8-86D8E21866DE",
    "form_completion_date": "2014-2-28",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 254,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 282,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f7a2b87f-c265-4cc5-a792-428756e31d8b",
    "patient_ID": "TCGA.A4.7287",
    "bcr_drug_barcode": "TCGA-A4-7287-D57042",
    "bcr_drug_uuid": "E701CC9C-CD73-46BB-A40A-89CB97BEF8FB",
    "form_completion_date": "2014-2-28",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 254,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 436,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f7a2b87f-c265-4cc5-a792-428756e31d8b",
    "patient_ID": "TCGA.A4.7287",
    "bcr_drug_barcode": "TCGA-A4-7287-D57043",
    "bcr_drug_uuid": "F7C82164-EBF6-4482-B240-1E92ED3F3933",
    "form_completion_date": "2014-2-28",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 290,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 436,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "D80F601B-1064-4FF0-9C51-7F6AFB22D1F5",
    "patient_ID": "TCGA.A4.A57E",
    "bcr_drug_barcode": "TCGA-A4-A57E-D64126",
    "bcr_drug_uuid": "671EBC9B-7F03-4D28-9F49-6C14627049BC",
    "form_completion_date": "2014-8-26",
    "pharmaceutical_therapy_drug_name": "AFINITOR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9fc40b03-0b56-4b1f-93ed-dbc455ae3fd9",
    "patient_ID": "TCGA.AL.3466",
    "bcr_drug_barcode": "TCGA-AL-3466-D4265",
    "bcr_drug_uuid": "12decace-308f-421d-b9ff-5db3ce417b54",
    "form_completion_date": "2010-11-15",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 33,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 138,
    "drug_units": "M[IU]",
    "drug_dose": 10,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "B06CDF61-61C9-4035-A55D-1EF21DC21069",
    "patient_ID": "TCGA.AL.A5DJ",
    "bcr_drug_barcode": "TCGA-AL-A5DJ-D43432",
    "bcr_drug_uuid": "BAC8233F-CFC9-4E90-ADCE-94632ACD7ADA",
    "form_completion_date": "2013-5-21",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 355,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 475,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "df135722-b98d-4dec-906d-77da13df39b9",
    "patient_ID": "TCGA.B9.4114",
    "bcr_drug_barcode": "TCGA-B9-4114-D30868",
    "bcr_drug_uuid": "52D39883-0543-4F39-90EE-F30376CFBA4D",
    "form_completion_date": "2012-4-17",
    "pharmaceutical_therapy_drug_name": "VOTRIENT",
    "days_to_drug_start": 722,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 755,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "df135722-b98d-4dec-906d-77da13df39b9",
    "patient_ID": "TCGA.B9.4114",
    "bcr_drug_barcode": "TCGA-B9-4114-D30869",
    "bcr_drug_uuid": "345F74A3-0B96-44F5-BFA3-E3D0341DDBC3",
    "form_completion_date": "2012-4-18",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "days_to_drug_start": 779,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "53d40ba3-c33b-4139-967d-5110884237a3",
    "patient_ID": "TCGA.BQ.5877",
    "bcr_drug_barcode": "TCGA-BQ-5877-D11669",
    "bcr_drug_uuid": "fc1ae4b4-adb3-4b12-a56d-3be51191b095",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "17-AAG",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 71,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 123,
    "drug_cycles": 4,
    "drug_units": "MG/M2",
    "drug_dose": 220,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "c793250d-1553-48e1-b6b2-aaffdfe5d39b",
    "patient_ID": "TCGA.BQ.5878",
    "bcr_drug_barcode": "TCGA-BQ-5878-D11677",
    "bcr_drug_uuid": "07bc9020-fd79-4d1e-9f6e-88bb314ebd67",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1086,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "b877d608-e4e0-4b28-9235-01dd65849cf7",
    "patient_ID": "TCGA.BQ.5879",
    "bcr_drug_barcode": "TCGA-BQ-5879-D11683",
    "bcr_drug_uuid": "75b02040-4cac-4c55-8cac-9624d0396034",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 192,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 430,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "ORAL"
  },
  {
    "bcr_patient_uuid": "b877d608-e4e0-4b28-9235-01dd65849cf7",
    "patient_ID": "TCGA.BQ.5879",
    "bcr_drug_barcode": "TCGA-BQ-5879-D11686",
    "bcr_drug_uuid": "09cfe30c-4580-4e9e-8d61-22a3ad817204",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 508,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 591,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "PREVIOUS TRIAL CLOSED, PRESCRIBED NEW MEDICAL TREATMENT"
  },
  {
    "bcr_patient_uuid": "b877d608-e4e0-4b28-9235-01dd65849cf7",
    "patient_ID": "TCGA.BQ.5879",
    "bcr_drug_barcode": "TCGA-BQ-5879-D11684",
    "bcr_drug_uuid": "096c882d-73d1-4ce0-b99e-f66051c9911b",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 472,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 493,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 15,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "b877d608-e4e0-4b28-9235-01dd65849cf7",
    "patient_ID": "TCGA.BQ.5879",
    "bcr_drug_barcode": "TCGA-BQ-5879-D11685",
    "bcr_drug_uuid": "a3353f9e-6314-42bf-bc56-ce685cfa9d4f",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 472,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 493,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "b877d608-e4e0-4b28-9235-01dd65849cf7",
    "patient_ID": "TCGA.BQ.5879",
    "bcr_drug_barcode": "TCGA-BQ-5879-D11687",
    "bcr_drug_uuid": "92e5e438-bb9c-4cdf-9daa-4ffd2a406599",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 612,
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 4,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "b877d608-e4e0-4b28-9235-01dd65849cf7",
    "patient_ID": "TCGA.BQ.5879",
    "bcr_drug_barcode": "TCGA-BQ-5879-D11682",
    "bcr_drug_uuid": "a16a1038-7644-408b-82d2-57efe3ebd2f0",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 192,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 430,
    "drug_cycles": 6,
    "drug_units": "MG/KG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "635fedd0-4daf-4d97-958a-3e0f49c1a708",
    "patient_ID": "TCGA.BQ.5889",
    "bcr_drug_barcode": "TCGA-BQ-5889-D11712",
    "bcr_drug_uuid": "3c76da39-e169-48d4-a832-d9b9eeecab9c",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 258,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 329,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "635fedd0-4daf-4d97-958a-3e0f49c1a708",
    "patient_ID": "TCGA.BQ.5889",
    "bcr_drug_barcode": "TCGA-BQ-5889-D11711",
    "bcr_drug_uuid": "177d264a-d902-47b5-b56f-d40515969719",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 175,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 241,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "635fedd0-4daf-4d97-958a-3e0f49c1a708",
    "patient_ID": "TCGA.BQ.5889",
    "bcr_drug_barcode": "TCGA-BQ-5889-D11708",
    "bcr_drug_uuid": "df32daa3-296c-4902-9b6b-adfbb57e7ac9",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 169,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "793f2df2-87a3-47e2-9cc1-a1a0e8487b51",
    "patient_ID": "TCGA.BQ.5893",
    "bcr_drug_barcode": "TCGA-BQ-5893-D11726",
    "bcr_drug_uuid": "1924e6cd-e36a-457f-abbc-0a82e2996fbf",
    "form_completion_date": "2011-5-13",
    "pharmaceutical_therapy_drug_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 35,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 183,
    "drug_cycles": 4,
    "drug_units": "MG",
    "drug_dose": 10,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "ae8bc8ea-29e6-4fe4-9095-d6d2655ee4f5",
    "patient_ID": "TCGA.BQ.7048",
    "bcr_drug_barcode": "TCGA-BQ-7048-D16729",
    "bcr_drug_uuid": "75b95e17-8704-4d76-b87d-38fc039d9fff",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2146,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2398,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 4,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "ae8bc8ea-29e6-4fe4-9095-d6d2655ee4f5",
    "patient_ID": "TCGA.BQ.7048",
    "bcr_drug_barcode": "TCGA-BQ-7048-D16728",
    "bcr_drug_uuid": "4f8b51af-83dc-41c0-b1ae-1dace933a9c7",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2042,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2146,
    "drug_cycles": 2,
    "drug_units": "MG",
    "drug_dose": 37.5,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "ae8bc8ea-29e6-4fe4-9095-d6d2655ee4f5",
    "patient_ID": "TCGA.BQ.7048",
    "bcr_drug_barcode": "TCGA-BQ-7048-D16727",
    "bcr_drug_uuid": "9f816529-f18e-463c-a9ed-28c8a5889d9c",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "PSMA DNA VACCINE",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 495,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 915,
    "pharma_type_other": "VACCINE",
    "drug_dose": 1500,
    "regimen_number": 1,
    "drug_route": "INTRAMUSCULAR",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "ae8bc8ea-29e6-4fe4-9095-d6d2655ee4f5",
    "patient_ID": "TCGA.BQ.7048",
    "bcr_drug_barcode": "TCGA-BQ-7048-D16995",
    "bcr_drug_uuid": "1b60764b-02aa-4b51-95dd-abf32830fd63",
    "form_completion_date": "2011-9-29",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1880,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2042,
    "drug_cycles": 4,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "36182304-2db7-446a-929c-7e43a47d863a",
    "patient_ID": "TCGA.BQ.7056",
    "bcr_drug_barcode": "TCGA-BQ-7056-D16919",
    "bcr_drug_uuid": "93c8a773-ce99-4e62-99aa-8012e4fcec0f",
    "form_completion_date": "2011-9-27",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 638,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 730,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "36182304-2db7-446a-929c-7e43a47d863a",
    "patient_ID": "TCGA.BQ.7056",
    "bcr_drug_barcode": "TCGA-BQ-7056-D16921",
    "bcr_drug_uuid": "ece7e5f9-3eb0-4d40-a6f2-ddcd5a252aaf",
    "form_completion_date": "2011-9-27",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 759,
    "drug_units": "MG",
    "drug_dose": 37.5,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "3cad2139-0bc5-4c8f-994a-018be7e2e6ea",
    "patient_ID": "TCGA.BQ.7058",
    "bcr_drug_barcode": "TCGA-BQ-7058-D16949",
    "bcr_drug_uuid": "35ffca29-f37c-4448-b1de-7706b494fe3c",
    "form_completion_date": "2011-9-27",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 216,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 295,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "3cad2139-0bc5-4c8f-994a-018be7e2e6ea",
    "patient_ID": "TCGA.BQ.7058",
    "bcr_drug_barcode": "TCGA-BQ-7058-D16950",
    "bcr_drug_uuid": "ce773ee2-3e68-45ca-8c06-ad9cb2cce66a",
    "form_completion_date": "2011-9-27",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 302,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 302,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3cad2139-0bc5-4c8f-994a-018be7e2e6ea",
    "patient_ID": "TCGA.BQ.7058",
    "bcr_drug_barcode": "TCGA-BQ-7058-D16948",
    "bcr_drug_uuid": "ef5a298f-abdc-46e7-a200-80ddefd71b26",
    "form_completion_date": "2011-9-27",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 203,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "drug_units": "MG",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "7f715b2e-fe7c-4a6e-95d1-fcab93b58f21",
    "patient_ID": "TCGA.G7.6789",
    "bcr_drug_barcode": "TCGA-G7-6789-D32228",
    "bcr_drug_uuid": "0E821DE1-BE11-4492-8585-47EB83DB1C5A",
    "form_completion_date": "2012-5-14",
    "pharmaceutical_therapy_drug_name": "INTRON A",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 74,
    "drug_cycles": 2,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "8fc6b46b-1c60-40b1-8924-0c2c9307c6e0",
    "patient_ID": "TCGA.G7.6793",
    "bcr_drug_barcode": "TCGA-G7-6793-D32255",
    "bcr_drug_uuid": "F862E286-F521-440E-B1C4-92056AA51064",
    "form_completion_date": "2012-5-14",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 57,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 258,
    "drug_cycles": 7,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 700
  },
  {
    "bcr_patient_uuid": "8fc6b46b-1c60-40b1-8924-0c2c9307c6e0",
    "patient_ID": "TCGA.G7.6793",
    "bcr_drug_barcode": "TCGA-G7-6793-D32256",
    "bcr_drug_uuid": "85EBC38B-B8C7-424F-B227-AB2E24023DC7",
    "form_completion_date": "2012-5-14",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 260,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 287,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "4afab224-f65e-48a8-8802-01138e210e29",
    "patient_ID": "TCGA.G7.7501",
    "bcr_drug_barcode": "TCGA-G7-7501-D32504",
    "bcr_drug_uuid": "A6B2BEC9-9011-47FC-A542-517FF36A5A04",
    "form_completion_date": "2012-5-30",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 110,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 506,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DB882417-AF3C-4A86-9004-F7E943798409",
    "patient_ID": "TCGA.G7.A8LD",
    "bcr_drug_barcode": "TCGA-G7-A8LD-D58202",
    "bcr_drug_uuid": "5D0D4B93-7C54-4E1D-891C-0264F8294D61",
    "form_completion_date": "2014-4-2",
    "pharmaceutical_therapy_drug_name": "AFINITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 424,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 446,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DB882417-AF3C-4A86-9004-F7E943798409",
    "patient_ID": "TCGA.G7.A8LD",
    "bcr_drug_barcode": "TCGA-G7-A8LD-D58201",
    "bcr_drug_uuid": "5F699533-4420-4A60-97CE-888019539FE6",
    "form_completion_date": "2014-4-3",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 340,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 417,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f24b772a-147e-4889-be23-e4ea10824d66",
    "patient_ID": "TCGA.GL.7966",
    "bcr_drug_barcode": "TCGA-GL-7966-D30452",
    "bcr_drug_uuid": "F3D955D8-33DE-4C38-91D3-988DB99CD0CA",
    "form_completion_date": "2012-4-10",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 96,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 96,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4F86DEC5-34A7-4C11-9578-7E007A203CBF",
    "patient_ID": "TCGA.IA.A83W",
    "bcr_drug_barcode": "TCGA-IA-A83W-D56320",
    "bcr_drug_uuid": "B7C47520-760B-411F-9753-7A115AB176EB",
    "form_completion_date": "2014-3-3",
    "pharmaceutical_therapy_drug_name": "RITUXAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 496,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 601,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4F86DEC5-34A7-4C11-9578-7E007A203CBF",
    "patient_ID": "TCGA.IA.A83W",
    "bcr_drug_barcode": "TCGA-IA-A83W-D56321",
    "bcr_drug_uuid": "5E01E73A-58DE-4BA7-8D65-58499C2097CA",
    "form_completion_date": "2014-3-3",
    "pharmaceutical_therapy_drug_name": "VINCRISTINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 496,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 601,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4F86DEC5-34A7-4C11-9578-7E007A203CBF",
    "patient_ID": "TCGA.IA.A83W",
    "bcr_drug_barcode": "TCGA-IA-A83W-D56322",
    "bcr_drug_uuid": "BB498EFE-DC3B-442F-B80C-4C28D72912EC",
    "form_completion_date": "2014-3-3",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 496,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 601,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4F86DEC5-34A7-4C11-9578-7E007A203CBF",
    "patient_ID": "TCGA.IA.A83W",
    "bcr_drug_barcode": "TCGA-IA-A83W-D56323",
    "bcr_drug_uuid": "D3BE17C8-B8E5-4020-8A86-95080E6E2C0D",
    "form_completion_date": "2014-3-3",
    "pharmaceutical_therapy_drug_name": "CYTOXAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 496,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 601,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7EF7C87E-6F11-4B9B-BB74-3C86036C8D20",
    "patient_ID": "TCGA.MH.A855",
    "bcr_drug_barcode": "TCGA-MH-A855-D59145",
    "bcr_drug_uuid": "AA69EE53-E1A2-4289-9F74-CEE2AE4586EF",
    "form_completion_date": "2014-5-1",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 86,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 205,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7EF7C87E-6F11-4B9B-BB74-3C86036C8D20",
    "patient_ID": "TCGA.MH.A855",
    "bcr_drug_barcode": "TCGA-MH-A855-D59147",
    "bcr_drug_uuid": "8CE69491-1200-4D73-A580-CA54DDC7A64D",
    "form_completion_date": "2014-5-1",
    "pharmaceutical_therapy_drug_name": "ALIMTA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 86,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 205,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "49A756A9-7125-4B1D-BCFC-6CC44BDF26F6",
    "patient_ID": "TCGA.SX.A7SM",
    "bcr_drug_barcode": "TCGA-SX-A7SM-D59368",
    "bcr_drug_uuid": "0A8BD6FE-31D6-480D-906A-CDFD599310A5",
    "form_completion_date": "2014-5-10",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 66,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 362,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  }
]
